First Indian study to correlate dose of Moxonidine and incidence of dry mouth in patients with chronic kidney disease
The sympathetic nervous system is known to play a central role in the pathophysiology of hypertension in CKD patients. A centrally acting sympatholytic drug would not only help reduce blood pressure but also intervene in multiple disease processes. Moxonidine differs from other available centrally acting antihypertensive by exhibiting only low affinity to central α2-adrenoceptors compared to I1-imidazoline receptors. The aim of the study was to evaluate whether moxonidine would result in dry mouth in patients of chronic kidney disease (CKD) and evaluate the presence of a dose dependent response. 55 adult hypertensive patients with CKD were included in the study. The patients were treated with moxonidine at different doses (0.2 mg/day 0.3 mg/day, 0.4 mg per day, 0.6 mg day and 0.9 mg/day) depending on the serum creatinine and eGFR. The highest incidence of dry mouth with moxonidine occurs at the dose of 0.4 mg and a ceiling effect is observed regarding the prevalence of dry mouth at doses above 0.4 mg.
Full Text Attachment